Riskpilot← Back to searchSign inGet full accessMedisem Oy
OYDissolvedY-tunnus 2354972-5Ribbingintie 105Medical specialists activities · NACE 8622Est. 20103 employees
Revenue 2024
EUR 599K
+3% vs 2023
EBITDA margin
59.3%
-8% vs 2023
Equity ratio
98.2%
Financial strength
Net profit 2024
EUR 218K
+4% vs 2023
| Revenue | EUR 599K | +3% |
| EBITDA | EUR 356K | -8% |
| Net profit | EUR 218K | +4% |
| Total assets | EUR 2,9M | +2% |
| Equity | EUR 2,9M | +1% |
| Employees | 3 | — |
Legal name
Medisem Oy
Y-tunnus number
2354972-5
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
31. elokuuta 2010
Share capital
EUR 2 500
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on Terveyden- ja sairaanhoitopalvelut, Äänituotanto, Arvopaperikaupan harjoitus, sekä kiinteistöjen, irtaimen omaisuuden ja asunto-osakkeiden osto, myynti, hallinta ja vuokraus.
Address
Ribbingintie 105
Phone
+358432003696
Email
medisemoy@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 623 | 761 | 746 | 584 | 599 |
| Staff expenses | −60 | −58 | −60 | −62 | −65 |
| EBITDA | 427 | 575 | 619 | 387 | 356 |
| Depreciation & amort. | −35 | −28 | −65 | −80 | −53 |
| EBIT | 392 | 548 | 554 | 306 | 303 |
| Net financials | −0 | 0 | −8 | −30 | −14 |
| Profit before tax | 392 | 548 | 546 | 277 | 289 |
| Tax | 78 | 110 | 109 | 67 | 71 |
| Net profit | 314 | 438 | 436 | 210 | 218 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 375 | 2 741 | 2 985 | 2 854 | 2 910 |
| Equity | 2 367 | 2 617 | 2 844 | 2 829 | 2 856 |
| Long-term debt | — | — | — | 0 | 0 |
| Short-term debt | 8 | 125 | 141 | 25 | 53 |
| Total debt | 8 | 125 | 141 | 25 | 53 |
EBITDA margin
59.3%
This company
15.8%
Market median
+275% vs market
20202024
Equity ratio
98.2%
This company
38.2%
Market median
+157% vs market
20202024
Return on equity
7.6%
This company
18.4%
Market median
-59% vs market
20202024
Net profit margin
36.4%
This company
8.1%
Market median
+349% vs market
20202024
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via PRH / YTJ · Period 2019-09-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TT | Audit | 2021 |
VV Deputy Member | Deputy Member | 2012 |
ES Chief Executive Officer | Chief Executive Officer | 2016 |
| Former (1) | ||
| Audit | 2010 – 2021 | |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairperson | 2012 | |
| Board of Directors | 2012 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medisem Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tarja Tuulikki Tolvanen | Audit | 0 companies |
| Riitta Tellervo Kallio-Saukkonen | Audit | 0 companies |
| Valeri Voloshin | Deputy Member | 0 companies |
| Egor Semenkov | Chief Executive Officer | 0 companies |
| Jekaterina Katja Semenkova | Chairperson | 0 companies |
| Sergey Semenkov | Board of Directors | 0 companies |
| Nikita Semenkov | Board of Directors | 0 companies |